𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-lasting benefits of botulinum toxin type B in Parkinson’s disease-related drooling

✍ Scribed by Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Maria Gabriella Ceravolo

Publisher
Springer
Year
2009
Tongue
English
Weight
240 KB
Volume
256
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Botulinum toxin type A for drooling in P
Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study
✍ Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Mari 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gla

Botulinum toxin type A for Levodopa-indu
Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: Unfavorable risk-benefit ratio
✍ Alberto J. Espay; Jennifer E. Vaughan; Rakesh Shukla; Maureen Gartner; Alok Saha 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 880 KB

originating from the peripheral rather than central retina. Correspondingly, VEP was also reported to be normal in MSA patients as it measures activity mainly originating from the central visual field. 7 Future studies will have to determine whether MSA patients show predominantly peripheral visual

Safety and efficacy of botulinum toxin t
Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: A prospective double-blind trial
✍ Robert Chinnapongse; Kristen Gullo; Paul Nemeth; Yuxin Zhang; Lynn Griggs 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 854 KB

## Abstract Sialorrhea (drooling) is a common symptom of Parkinson's disease (PD) that can significantly impair a patient's health and quality of life. Fifty‐four PD subjects with troublesome sialorrhea were enrolled using a multicenter, randomized, double‐blind, sequential‐dose escalation design i